222 related articles for article (PubMed ID: 25029663)
1. Toward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
Johnson KM; Parsons ZD; Barnes CL; Gates KS
J Org Chem; 2014 Aug; 79(16):7520-31. PubMed ID: 25029663
[TBL] [Abstract][Full Text] [Related]
2. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
Hunter FW; Wang J; Patel R; Hsu HL; Hickey AJ; Hay MP; Wilson WR
Biochem Pharmacol; 2012 Mar; 83(5):574-85. PubMed ID: 22182429
[TBL] [Abstract][Full Text] [Related]
3. 3-amino-1,2,4-benzotriazine 4-oxide: characterization of a new metabolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
Fuchs T; Chowdhury G; Barnes CL; Gates KS
J Org Chem; 2001 Jan; 66(1):107-14. PubMed ID: 11429885
[TBL] [Abstract][Full Text] [Related]
4. DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
Birincioglu M; Jaruga P; Chowdhury G; Rodriguez H; Dizdaroglu M; Gates KS
J Am Chem Soc; 2003 Sep; 125(38):11607-15. PubMed ID: 13129365
[TBL] [Abstract][Full Text] [Related]
5. Oxidative DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
Kotandeniya D; Ganley B; Gates KS
Bioorg Med Chem Lett; 2002 Sep; 12(17):2325-9. PubMed ID: 12161126
[TBL] [Abstract][Full Text] [Related]
6. Isotopic labeling experiments that elucidate the mechanism of DNA strand cleavage by the hypoxia-selective antitumor agent 1,2,4-benzotriazine 1,4-di-N-oxide.
Shen X; Rajapakse A; Gallazzi F; Junnotula V; Fuchs-Knotts T; Glaser R; Gates KS
Chem Res Toxicol; 2014 Jan; 27(1):111-8. PubMed ID: 24328261
[TBL] [Abstract][Full Text] [Related]
7. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions.
Hwang JT; Greenberg MM; Fuchs T; Gates KS
Biochemistry; 1999 Oct; 38(43):14248-55. PubMed ID: 10571998
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of the cytotoxicity of the anticancer agent tirapazamine by benzotriazine N-oxides: the role of redox equilibria.
Anderson RF; Shinde SS; Hay MP; Denny WA
J Am Chem Soc; 2006 Jan; 128(1):245-9. PubMed ID: 16390153
[TBL] [Abstract][Full Text] [Related]
9. Initiation of DNA strand cleavage by 1,2,4-benzotriazine 1,4-dioxide antitumor agents: mechanistic insight from studies of 3-methyl-1,2,4-benzotriazine 1,4-dioxide.
Junnotula V; Sarkar U; Sinha S; Gates KS
J Am Chem Soc; 2009 Jan; 131(3):1015-24. PubMed ID: 19117394
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
Monge A; Palop JA; López de Ceráin A; Senador V; Martínez-Crespo FJ; Sainz Y; Narro S; García E; de Miguel C; González M
J Med Chem; 1995 May; 38(10):1786-92. PubMed ID: 7752202
[TBL] [Abstract][Full Text] [Related]
11. Putative electron-affinic radiosensitizers and markers of hypoxic tissue: Synthesis and preliminary in vitro biological characterization of C3-amino-substituted benzotriazine dioxides (BTDOs).
Elsaidi HR; Yang XH; Ahmadi F; Weinfeld M; Wiebe LI; Kumar P
Eur J Med Chem; 2019 Mar; 165():216-224. PubMed ID: 30684798
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
13. Oxidation of 2-deoxyribose by benzotriazinyl radicals of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides.
Shinde SS; Anderson RF; Hay MP; Gamage SA; Denny WA
J Am Chem Soc; 2004 Jun; 126(25):7865-74. PubMed ID: 15212534
[TBL] [Abstract][Full Text] [Related]
14. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
Wang J; Foehrenbacher A; Su J; Patel R; Hay MP; Hicks KO; Wilson WR
Clin Cancer Res; 2012 Mar; 18(6):1684-95. PubMed ID: 22167409
[TBL] [Abstract][Full Text] [Related]
15. Exploiting the Inherent Photophysical Properties of the Major Tirapazamine Metabolite in the Development of Profluorescent Substrates for Enzymes That Catalyze the Bioreductive Activation of Hypoxia-Selective Anticancer Prodrugs.
Shen X; Laber CH; Sarkar U; Galazzi F; Johnson KM; Mahieu NG; Hillebrand R; Fuchs-Knotts T; Barnes CL; Baker GA; Gates KS
J Org Chem; 2018 Mar; 83(6):3126-3131. PubMed ID: 29461834
[TBL] [Abstract][Full Text] [Related]
16. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
Tercel M; Wilson WR; Anderson RF; Denny WA
J Med Chem; 1996 Mar; 39(5):1084-94. PubMed ID: 8676343
[TBL] [Abstract][Full Text] [Related]
18. DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro-2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide.
Junnotula V; Rajapakse A; Arbillaga L; de Cerain AL; Solano B; Villar R; Monge A; Gates KS
Bioorg Med Chem; 2010 May; 18(9):3125-32. PubMed ID: 20371184
[TBL] [Abstract][Full Text] [Related]
19. Radical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides.
Anderson RF; Shinde SS; Hay MP; Gamage SA; Denny WA
Org Biomol Chem; 2005 Jun; 3(11):2167-74. PubMed ID: 15917906
[TBL] [Abstract][Full Text] [Related]
20. Photodegradation of the benzotriazine 1,4-Di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solution.
Gu Y; Jaiswal JK; Wang J; Hicks KO; Hay MP; Wilson WR
J Pharm Sci; 2014 Nov; 103(11):3464-3472. PubMed ID: 25212501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
